{{expand language|1=en|page=Pioglitazone|time=2019-04-19T02:35:44+00:00}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464207213
| IUPAC_name = (''RS'')-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione
| image = Pioglitazone.svg
| width = 271
| chirality = <!-- [[Racemic_mixture|Racemic mixture]] -->[[外消旋混合物|外消旋混合物]]
| image2 = Pioglitazone ball-and-stick model.png

<!--Clinical data-->
| tradename = Actos, others
| Drugs.com = {{drugs.com|monograph|pioglitazone-hydrochloride}}
| MedlinePlus = a699016
| licence_EU = yes
| licence_US = Actos
| pregnancy_category = C
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = By mouth
| class = <!-- 页面不存在 -->[[Thiazolidinedione|Thiazolidinedione]]

<!--Pharmacokinetic data-->
| protein_bound = >99%
| metabolism = liver (CYP2C8)
| elimination_half-life = 3–7 hours
| excretion = in bile

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 111025-46-8
| ATC_prefix = A10
| ATC_suffix = BG03
| PubChem = 4829
| IUPHAR_ligand = 2694
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01132
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4663
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = X4OV71U42S
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08378
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8228
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 595

<!--Chemical data-->
| C=19 | H=20 | N=2 | O=3 | S=1
| molecular_weight = 356.44 g/mol
| smiles = O=C1NC(=O)SC1Cc3ccc(OCCc2ncc(cc2)CC)cc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HYAFETHFCAUJAY-UHFFFAOYSA-N
| melting_point = 183
| melting_high = 184
}}
<!-- Definition and uses -->
'''吡格列酮'''（{{lang |en |Pioglitazone}}）是一種專門用於治療[[2型糖尿病|2型糖尿病]]<ref name=BNF76/>的口服藥物<ref name=AHFS2019>{{cite web |title=Pioglitazone Hydrochloride Monograph for Professionals |url=https://www.drugs.com/monograph/pioglitazone-hydrochloride.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |accessdate=3 March 2019 |language=en}}</ref>，屬於[[噻唑烷二酮|噻唑烷二酮]]类（[[活化受体调节剂|活化受体调节剂]]）藥物的一種。

==參考文獻==
{{Reflist|refs=
<ref name=BNF76>{{cite book
 |title=British national formulary : BNF 76 |edition=76th |date=2018 |publisher=Pharmaceutical Press |isbn=9780857113382 |pages=694 |language=en }}</ref>
}}

==外部連結==
*[https://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a699016.html Pioglitazone FAQ]
*[http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Pioglitazone U.S. National Library of Medicine: Drug Information Portal - Pioglitazonee]

{{Oral hypoglycemics}}
[[Category:礼来公司|Category:礼来公司]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:吡啶|Category:吡啶]]
[[Category:IARC第2A类致癌物质|Category:IARC第2A类致癌物质]]